Visit RabiesWatch for more information on rabies exposures and the virus in the US.

Postexposure Prophylaxis (PEP) for Rabies

More than 60,000 people report coming in contact with potentially rabid animals and receive rabies PEP each year.1

According to the Centers for Disease Control and Prevention (CDC), rabies is almost always fatal, but it is almost 100% preventable.  Comprehensive treatment can only be provided by a rabies immune globulin, such as HyperRAB (rabies immune globulin [human]) 300 IU/mL, in conjunction with a vaccine.3

Be sure to follow the CDC PEP schedule4

CDC postexposure prophylaxis schedule

For more information, recommendations, and guidelines, visit the CDC Advisory Committee on Immunization Practices (ACIP).


Imminent Threat, Immediate Protection

Vaccines can take weeks to build efficacy, but HyperRAB provides immediate protection. This allows the vaccine the time needed to establish active immunity, giving your patients the critical protection they need now.5

HyperRAB contains high titers of rabies antibodies for PEP, providing rapid immune protection. Along with appropriate wound cleansing, a human rabies immune globulin such as HyperRAB is recommended by the CDC and World Health Organization (WHO) to be administered at the same time as the rabies vaccine in previously unvaccinated persons, immediately following a transdermal bite or scratch by an animal suspected of being rabid.3,6
For unvaccinated individuals, the combination of human rabies immune globulin and vaccine is recommended for both bite and nonbite exposures, regardless of the time interval between exposure and initiation of PEP.
If PEP has been initiated and appropriate laboratory diagnostic testing (ie, the direct fluorescent antibody test) indicates that the animal that caused the exposure was not rabid, PEP may be discontinued.3

Dosing Recommendations

The recommended dose for HyperRAB is 20 IU/kg or 0.0665 mL/kg of body weight given at time of first vaccine dose. HyperRAB may also be given up to the eighth day after the first dose of vaccine. Do not exceed the recommended dose, as this could partially suppress active production of rabies antibody.2

HyperRAB® (rabies immune globulin [human]) 300 IU/mL
High-potency formulation

HyperRAB Product Information

Indication and Usage

HYPERRAB® (rabies immune globulin [human]) is indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies.

Limitations of Use 

Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.

For unvaccinated persons, the combination of HYPERRAB and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of postexposure prophylaxis.

Beyond 7 days (after the first vaccine dose), HYPERRAB is not indicated since an antibody response to vaccine is presumed to have occurred.

Important Safety Information

For infiltration and intramuscular use only.

Severe hypersensitivity reactions may occur with HYPERRAB. Patients with a history of prior systemic allergic reactions to human immunoglobulin preparations are at a greater risk of developing severe hypersensitivity and anaphylactic reactions. Have epinephrine available for treatment of acute allergic symptoms, should they occur.

HYPERRAB is made from human blood and may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most common adverse reactions in >5% of subjects during clinical trials were injection-site pain, headache, injection-site nodule, abdominal pain, diarrhea, flatulence, nasal congestion, and oropharyngeal pain.

Do not administer repeated doses of HYPERRAB once vaccine treatment has been initiated as this could prevent the full expression of active immunity expected from the rabies vaccine.

Other antibodies in the HYPERRAB preparation may interfere with the response to live vaccines such as measles, mumps, polio, or rubella. Defer immunization with live vaccines for 4 months after HYPERRAB administration.  

Please see full Prescribing Information for HYPERRAB.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.


  1. Data on file, Grifols.
  2. HyperRAB (rabies immune globulin [human]) Prescribing Information. Grifols.
  3. Centers for Disease Control and Prevention. Human rabies prevention — United States, 2015: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2008;57(RR03):my1-26,28.
  4. Rupprecht CE, Briggs D, Brown CM, et al; Centers for Disease Control and Prevention (CDC). Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2010;59(RR-2):1-9.
  5. Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond). 2007;57(8):552-556.
  6. World Health Organization (WHO). Rabies. Current strategies for human rabies pre and post-exposure prophylaxis. WHO website. Updated 2016. Accessed April 11, 2016.
  7. Gelfand EW. Differences between IGIV products: impact on clinical outcomes. Int Immunopharmacol. 2006;6(4):592-599.
  8. Bertolini J. The purification of plasma proteins for therapeutic use. In: Simon TL, McCullough SJ, Snyder EL, Solheim BJ, Strauss RG, eds. Rossi's Principles of Transfusion Medicine. 5th ed. London, UK: John Wiley & Sons, Ltd; 2016.
  9. Barnette D, Roth NJ, Hotta J, et al. Pathogen safety profile of a 10% IgG preparation manufactured using a depth filtration-modified process. Biologicals. 
  10. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion. 1999;39(11-12):1160-1168.
  11. European Medicines Agency. Guideline on the warning on transmissible agents in summary of product characteristics (SmPCs) and package leaflets for plasma-derived medicinal products. EMA/CHMP/BWP/360642/2010 rev. 1. 15 December 2011.
  12. European Medicines Agency. CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. EMA/CHMP/BWP/303353/2010. 23 June 2011.